Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Russian Trial ALGORITHM: Implementation of Combined Antihypertensive and Hypolipidemic Treatment for Clinical Efficacy Achievement in Routine Clinical Practice

https://doi.org/10.20996/1819-6446-2019-15-6-779-788

Full Text:

Abstract

Aim. To study the clinical outcomes (achievement of target blood pressure [BP]) and tolerability of antihypertensive and hypolipidemic therapy with fixed combinations of indapamide/perindopril, amlodipine/perindopril, amlodipine/indapamide/perindopril and rosuvastatin in patients with hypertension and high/very high cardiovascular risk in real clinical practice.

Material and methods. The study included 16,788 patients from 104 cities of the Russian Federation. The duration of observation was 12 weeks. All patients had three monitoring visits. BP level was measured twice during the visits: the arithmetic mean of the obtained parameters was calculated. The results of the study were analyzed and presented by descriptive statistics.

Results. The average age of the patients was 60.6±10.2 years; 42.2% of the patients were men and 57.8% women. Patients who demonstrated systolicdiastolic hypertension (BP>140/90 mm Hg) at the initial visit accounted for 73.9% (n=12,413) of the total number of participants. The average level of systolic BP at the inclusion into the study was 162.94±13.07 mm Hg, the level of diastolic BP was 93.43±8.61 mm Hg. As expected, the Russian population consists of over 90% of patients with very high (57%; n=9,586) and high (35.9%; n=6,022) additional cardiovascular risk. Despite the fact that the overwhelming majority of patients with hypertension had a high and very high additional risk, more than a third of patients received monotherapy to control their BP level (36.8%; n=6,182), while 13.8% of patients (n=2,321) had never received antihypertensive therapy before. According to the results of therapy with combination drugs based on perindopril, 92.7% of patients managed to reach the target BP levels of <140/90 mm Hg. After treatment the average level of systolic BP decreased from 162.94±13.07 mm Hg to 127.80±7.56 mm Hg, and the level of diastolic BP – from 93.43±8.61 mm Hg to 78.54±5.59. Adherence to the treatment in more than 97% of cases was recognized as very high and high. Only 10 adverse events were recorded on a large sample of patients during 12 weeks of treatment.

Conclusion. In the Russian population, 73.9% of patients with hypertension and high/very high risk do not achieve the target BP levels. Application of combined therapy based on fixed combinations with perindopril allows achieving effective BP control in 93% of patients with hypertension having high and very high risk during 12 weeks with good tolerability of treatment.

About the Author

D. A. Napalkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Dmitry A. Napalkov – MD, PhD, Professor, Chair of Faculty Therapy №1

Trubetskaya ul. 8-2, Moscow, 119991



References

1. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;00:1-98. DOI:10.1093/eurheartj/ehy339.

2. Shalnova S.A., Balanova Y.A., Konstantinov V.V., et al. Arterial hypertension: prevalence, awareness, antihypertensive pharmaceutical treatment, treatment effectiveness in Russian population. Russian Journal of Cardiology. 2006;(4):45-50 (In Russ.) DOI:10.15829/1560-4071-2006-445-50.

3. Badin Y.V., Fomin I.V., Belenkov Y.N., et al. EPOHA-AG 1998–2017: dynamics of prevalence, awareness of arterial hypertension, treatment coverage and effective control of blood pressure in the European part of the Russian Federation. Kardiologiia. 2019;59(1S):34-42 DOI:10.18087/cardio.2445.

4. Drapkina O.M. Combination therapy of high-risk patients in real clinical practice. Results of SYNERGY study. Part 1. Antihypertensive branch. Rational Pharmacotherapy in Cardiology. 2017;13(2):155163. (In Russ.) DOI:10.20996/1819-6446-2017-13-2-155-163.

5. Rea F., Corrao G., Merlino L., Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654-61. DOI:10.1093/eurheartj/ehy420.

6. Cuende J.I., Cuende N., Calaveras-Lagartos J. How to calculate vascular age with the SCOREproject scales: a new method of cardiovascularrisk evaluation. Eur Heart J. 2010;31:2351-8. DOI:10.1093/eurheartj/ehq205.


For citation:


Napalkov D.A. Russian Trial ALGORITHM: Implementation of Combined Antihypertensive and Hypolipidemic Treatment for Clinical Efficacy Achievement in Routine Clinical Practice. Rational Pharmacotherapy in Cardiology. 2019;15(6):779-788. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-6-779-788

Views: 297


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)